Skip to main content
Log in

Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1)

Clinical Pharmacology and Potential Treatment of Endocrine and Metabolic Disorders

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Insulin-like growth factor (IGF-1) is a polypeptide of 70 amino acids. The circulatory form of IGF-1 is synthesised in the liver. The metabolic activity of IGF-1 is regulated by 6 IGF-binding proteins (BPs), the most important being IGFBP-3. IGF-1 acts via its own receptor, which resembles that of insulin. It has been demonstrated that the effects of growth hormone (GH) on protein metabolism, including growth and the effect on nerve tissue versus trophic effects, are mediated by IGF-1, whereas these 2 hormones are antagonistic in their effects on insulin and some aspects of lipid metabolism. This paper reviews present knowledge on the physiological role of IGF-1 and clinical effects of recombinant IGF-1 (somatomedin-1).

The biosynthesis of somatomedin-1 in 1986 enabled the initiation of clinical trials. Somatomedin-1 has many potential uses in the clinic. The most important is replacement therapy in primary IGF-1 deficiency, such as Laron syndrome (primary GH resistance or insensitivity) and in patients who have developed antibodies to hGH. In Laron syndrome, which is characterised by dwarfism, somatomedin-1 stimulates growth and increases muscle and bone mass, as well as normalising blood chemistry. In types 1 and 2 (insulin-dependent and non—insulin-dependent) diabetes mellitus, somatomedin-1 increases the sensitivity to insulin and improves glucose utilisation.

Experimental studies indicate that IGF-1 has a role in nerve tissue metabolism, and in humans may contribute to healing of injured nerve tissue. Other current clinical trials using the anabolic properties of somatomedin-1 are studying its effect on osteoporosis, catabolic states (burns, post-operation, AIDS) and haematopoietic disorders. Adverse effects of somatomedin-1 appear to be related to overdosage.

In conclusion, somatomedin-1 is an important hormone which has a promising role as replacement therapy and appears to have many other potential applications in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Merimee T, Laron Z. Growth hormone, IGF-I and growth: New views of old concepts. London-Tel Aviv: Freund Publishing House Ltd, Mod Endocrinol Diabetes 1996

    Google Scholar 

  2. Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature 1980; 287: 781–7

    Article  PubMed  CAS  Google Scholar 

  3. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769–76

    PubMed  CAS  Google Scholar 

  4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3–34

    PubMed  CAS  Google Scholar 

  5. Zapf J, Gosteli-Peter M, Schmid C. Insulin-like growth factor binding proteins (IGFBPs). In: Merimee T, Laron Z, editors. Growth hormone, IGF-I and growth: new views of old concepts. London-Tel Aviv: Freund Publishing House Ltd.,Mod Endocrinol Diabetes 1996: 45–71

    Google Scholar 

  6. Kaneti H, Silbergeld A, Klinger B, et al. Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein. Eur J Endocrinol 1997; 137: 626–30

    Article  Google Scholar 

  7. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular biology of IGF-I receptor. In: Merimee T, Laron Z, editors. Growth hormone, IGF-I and growth: new views of old concepts. London-Tel Aviv: Freund Publishing House Ltd.,Mod Endocrinol Diabetes 1996: 73–99

    Google Scholar 

  8. Adamo ML. Regulation of insulin-like growth factor I gene expression. Diabetes Rev 1995; 3: 2–27

    Google Scholar 

  9. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38–61

    Google Scholar 

  10. Silbergeld A, Litwin A, Bruchis S, et al. Insulin-like growth factor (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol 1986; 25: 67–74

    Article  CAS  Google Scholar 

  11. Guler HP, Zapf J, Schmid C, et al. Insulin like growth factors I and II in healthy man. Estimations of half lives and production rates. Acta Endocrinol 1989; 121: 753–8

    PubMed  CAS  Google Scholar 

  12. Laron Z. Prismatic cases: Laron Syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526–73

    Article  PubMed  CAS  Google Scholar 

  13. Phillips LS, Unterman TG. Somatomedin activity in disorders of nutrition and metabolism. In: Daughaday WH, editor. Clinics in endocrinology and metabolism: tissue growth factors. London: WB Saunders 1984: 145–89

    Google Scholar 

  14. Niwa M, Sato Y, Saito Y, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 59Val somatomedin C. Ann NY Acad Sci 1986; 469: 31–52

    Article  PubMed  CAS  Google Scholar 

  15. Laron Z. Somatomedin I in clinical use: facts and potential. Drugs 1993; 45: 1–8

    Article  PubMed  CAS  Google Scholar 

  16. Clemmons DR, Underwood LE. Clinical review 59. Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994; 79: 4–6

    Article  PubMed  CAS  Google Scholar 

  17. Zapf J. Insulin-like growth factor (IGF)-I: an alternative for growth hormone (GH)? Int Growth Monit 1996; 6: 2–6

    Google Scholar 

  18. Guler HP, Zapf J, Froesch ER. Short term metabolic effects of recombinant human insulin like growth factor in healthy adults. N Engl J Med 1987; 317: 137–40

    Article  PubMed  CAS  Google Scholar 

  19. Froesch ER, Guler HP, Schmid C, et al. Therapeutic potential of insulin-like growth factor I. Trends Endocrinol Metab 1990; 1: 254–60

    Article  PubMed  CAS  Google Scholar 

  20. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. Hemodynamic and metabolic responses to human insulin like growth factor (IGF-I) in men. In: Spencer M, editor. Modern concepts of insulin like growth factor. Asterdam: Elsevier Science, 1991: 219–24

    Google Scholar 

  21. Zenobi PD, Graf S, Froesch ER. Effects of recombinant human insulin like growth factor I (rIGF-I) infusion on glucose tolerance, insulin levels and insulin secretion in man. [abstract no. 45]. Diabetes 1991; 40(Suppl. 1): 12A

    Google Scholar 

  22. Takano K, Hizuka N, Asakawa K, et al. Effects of s.c. administration of recombinant insulin like growth factor I (IGF-I) on normal human patients. Endocrinol Jpn 1990; 37: 309–17

    Article  PubMed  CAS  Google Scholar 

  23. Takano K, Hizuka N, Shizume K, et al. Repeated s.c. administration of recombinant insulin like growth factor I (IGF-I) to human patients for 7 days. Growth Regul 1991; 1: 23–8

    PubMed  CAS  Google Scholar 

  24. Laron Z, Klinger B, Erster B, et al. Effects of acute administration of insulin like growth. factor I in patients with Laron-type dwarfism. Lancet 1988; ii: 1170–2

    Article  Google Scholar 

  25. Laron Z, Klinger B, Silbergeld A, et al. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378–82

    PubMed  CAS  Google Scholar 

  26. Laron Z, Blum W, Chatelain P, et al. Classification of growth hormone insensitivity syndrome. J Pediatr 1993; 122: 241

    Article  PubMed  CAS  Google Scholar 

  27. Rosenfeld RG, Rosenbloom AL, Guevarra-Aguirre J. Growth hormone (GH) insensitivity to primary Gh receptor deficiency. Endocr Rev 1994; 15: 369–90

    PubMed  CAS  Google Scholar 

  28. Klinger B, Garty M, Silbergeld A, et al. Elimination characteristics of intravenously administered rIGF-I in Laron type dwarfs (LTD). Dev Pharmacol Ther 1990; 15: 196–9

    PubMed  CAS  Google Scholar 

  29. Eshet R, Dux Z, Silbergeld A, et al. Erythrocytes from patients with low serum concentrations of IGF-I have an increase in receptor sites for IGF-I. Acta Endocrinol (copenh) 1991; 125: 354–8

    CAS  Google Scholar 

  30. Eshet R, Klinger B, Silbergeld A, et al. Modulation of insulin like growth factor I (IGF-I) binding sites on erythrocytes by IGF-I treatment in patients with Laron syndrome (LS). Regul Pept 1993; 48: 233–9

    Article  PubMed  CAS  Google Scholar 

  31. Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol 1992; 36: 301–4

    Article  CAS  Google Scholar 

  32. Gourmelen M, Perin L, Binoux M. Interest of IGF-I and IGF-BPs measurements in patients with Laron-type dwarfism. In: Laron Z, Parks JS, editors. Lessons from Laron Syndrome (LS) 1966-1992. Bsel-New York: Karger, 1993: 181–184. Pediatric and Adolescent Endocrinology, vol. 24.

    Google Scholar 

  33. Gil-Ad I, Koch Y, Silbergeld A, et al. Differential effect of insulin-like growth factor I (IGF-I) and growth hormone (GH) on hypothalamic regulation of GH secretion in the rat. J Endocrinol Invest 1996; 19: 542–7

    PubMed  CAS  Google Scholar 

  34. Laron Z, Klinger B, Jensen LT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin. Endocrinol 1991; 35: 145–50

    Article  CAS  Google Scholar 

  35. Klinger B, Jensen LT, Silbergeld A, et al. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol 1996; 45: 423–9

    Article  Google Scholar 

  36. Laron Z, Anin S, Klipper-Aubach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258–61

    Article  PubMed  CAS  Google Scholar 

  37. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121: 641–6

    Article  PubMed  CAS  Google Scholar 

  38. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994; 8: 684–8

    Article  PubMed  CAS  Google Scholar 

  39. Kaneti H, Karasik A, Klinger B, et al. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor — binding protein 3 in the absence of growth hormone activity. Acta Endocrinol 1993; 128: 144–9

    Google Scholar 

  40. Rechler MM, Brown AL. Insulin-like growth factor binding proteins: gene structure and expression. Growth Regul 1992; 2: 55–68

    PubMed  CAS  Google Scholar 

  41. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron Syndrome. Clin Endocrinol 1998; 48: 81–87

    Article  CAS  Google Scholar 

  42. Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res 1995; 44: 253–64

    Article  PubMed  CAS  Google Scholar 

  43. Backeljauw PF, Underwood LE, the GHIS collaborative group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome — a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3312–7

    Article  PubMed  CAS  Google Scholar 

  44. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron Syndrome. J Pediatr Endocrinol Metab 1995; 8: 149–58

    Article  PubMed  CAS  Google Scholar 

  45. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629–33

    Article  PubMed  CAS  Google Scholar 

  46. Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393–8

    Article  PubMed  CAS  Google Scholar 

  47. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol 1994; 41: 631–8

    Article  CAS  Google Scholar 

  48. Oliviera SB, Arnhold IJP, Phillips JA III. Treatment with recombinant IGF-I for patients with growth hormone (GH) gene deletion. [abstract no.8] Pediat Res 1997; 41: 301

    Article  Google Scholar 

  49. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992; 8: 229–57

    Article  PubMed  CAS  Google Scholar 

  50. Cheetham TD, Jones J, Taylor AM, et al. The effects of recombinant human insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin dependent) diabetes mellitus. Diabetologia 1993; 36: 678–81

    Article  PubMed  CAS  Google Scholar 

  51. Cheetham TD, Clayton KL, Taylor AM, et al. The effects of recombinant human insulin-like growth factor-I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994; 40: 515–22

    Article  CAS  Google Scholar 

  52. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1040–5

    Article  PubMed  CAS  Google Scholar 

  53. Cheetham TD, Connors M, Clayton K, et al. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin- dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I). Clin Endocrinol 1997; 46: 415–24

    Article  CAS  Google Scholar 

  54. Dunger DB, Cheetham TD, Holly JMP, et al. Does recombinant insulin-like growth factor-I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence. Acta Paediatr Scand 1993; (Suppl) 388: 49–52

    CAS  Google Scholar 

  55. Dunger DB, Acerini CL, Cheetham TD, et al. How does rhIGF-I replacement improve insulin sensitivity in insulin dependent diabetes mellitus? J Pediat Endocrinol Metab 1997; 10: 117–22

    Article  Google Scholar 

  56. Bereket A, Lang CH, Blethen SL, et al. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282–8

    Article  PubMed  CAS  Google Scholar 

  57. Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199–204

    Article  PubMed  CAS  Google Scholar 

  58. Quattrin T, Thrailkill K, Baker L, et al. Dual recombinant replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Diabetes Care 1997; 20: 374–80

    Article  PubMed  CAS  Google Scholar 

  59. Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor I (IGF-I) in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF- binding protein system. J Clin Endocrinol Metab 1997; 82: 1181–7

    Article  PubMed  CAS  Google Scholar 

  60. Usala A-L, Madigan T, Burguera B, et al. Brief report: treatment of insulin- resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. N Engl J Med 1992; 327: 853–7

    Article  PubMed  CAS  Google Scholar 

  61. Longo N, Singh R, Griffin LD, et al. Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor I. J Clin Endocrinol Metab 1994; 79: 799–805

    Article  PubMed  CAS  Google Scholar 

  62. Usala A-L, Madigan T, Burguera B, et al. High dose intravenous, but not low dose subcutaneous insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 435–40

    Article  PubMed  CAS  Google Scholar 

  63. Backeljauw PF, Alves C, Eidson M, et al. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. Pediatr Res 1994; 36: 749–54

    Article  PubMed  CAS  Google Scholar 

  64. Schalch DS, Turman NJ, Marcsisin VS, et al. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563–8

    Article  PubMed  CAS  Google Scholar 

  65. Young SCJ, Clemmons DR. Changes in insulin-like growth factor (IGF)- binding proteins after IGF-I injections in non-insulin-dependent diabetics. J Clin Endocrinol Metab 1994; 78: 609–14

    Article  PubMed  CAS  Google Scholar 

  66. Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369–74

    Article  PubMed  CAS  Google Scholar 

  67. Moses AC. Recombinant human insulin-like growth factor as a therapeutic agent for severe insulin resistance and type II diabetes mellitus. J Pediatr Endocrinol Metab 1997; 10: 123–30

    Article  Google Scholar 

  68. rhIGF-I in NIDDM study group. Evidence from a dose-ranging study that recombinant insulin-like growth factor-I (rhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (NIDDM) [abstract no. 94] Diabetes 1996; 45(Suppl. 2): 27A

    Google Scholar 

  69. Laron Z, Karp M. Carbohydrate metabolism in the syndrome of familial dwarfism and high plasma immunoreactive growth hormone (Laron type dwarfism). In: Podolsky S, Wiswanathan M, editors. Secondary diabetes: the spectrum of the diabetic syndrome. Nw York: Raven Press, 1980: 363–71

    Google Scholar 

  70. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome), before and during insulin-like growth factor I treatment. Metabolism 1995; 44(Suppl 4): 113–8

    Article  PubMed  CAS  Google Scholar 

  71. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. J Pediatr Endocrinol Metab 1997; 10: 105–15

    Article  Google Scholar 

  72. Tamborlane WV, Hintz RL, Bergman M, et al. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303–7

    Article  PubMed  CAS  Google Scholar 

  73. Annotations: insulin and insulin-like growth factors in diabetes mellitus. Arch Dis Child 1995; 72: 469-77

  74. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease (Review). Atherosclerosis 1994; 108: 111–26

    Article  PubMed  CAS  Google Scholar 

  75. Utennann G. The mysteries of lipoprotein(a). Rev Sci 1989; 246: 904–10

    Google Scholar 

  76. Eden S, Oscarsson J. GH and IGF-I in lipoprotein metabolism. J Pediatr Endocrinol Metab 1997; 10: 137–41

    Article  Google Scholar 

  77. Laron Z, Wang XL, Silbergeld, et al. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377–81

    Article  PubMed  CAS  Google Scholar 

  78. Laron Z, Klinger B, Silbergeld A, et al. Opposing effects of growth hormone and insulin-like growth factor I on serum lipoprotein. J Pediatr Endocrinol Metab 1997; 10: 143–9

    Article  Google Scholar 

  79. Hirschberg R, Kopple JD. Insulin-like growth factor I and renal function. Diabetes Rev 1995; 3: 177–95

    Google Scholar 

  80. Laron Z, Wang XL, Klinger B, et al. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996; 9: 533–7

    Article  PubMed  CAS  Google Scholar 

  81. Bondy CA, Lee W-H. Patterns of insulin-like growth factor and IGF receptor gene expression in the brain: functional implications. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 33-43

    Google Scholar 

  82. Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 33-43

    Google Scholar 

  83. Gluckman PD, Guan J, Beilharz EJ, et al. The role of the insulin-like growth factor system in neuronal rescue. The role of insulin-like growth factors in the nervous system. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 138-48

    Google Scholar 

  84. Bozyczko-Coyne D, Glicksman MA, Prantner JE, et al. IGF-I supports the survival and/or differentiation of multiple types of central nervous system neurons. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 311-3

    Google Scholar 

  85. Carlsson-Skwirut C, Jornwall H, Holmgren A, et al. Isolation and characterization of varian IGF-I as well as ICF-2 from adult human brain FEBS Lett 1986; 201: 46–50

    CAS  Google Scholar 

  86. Doyle KL, Sara VR, Plenderleith MB. Localisation of insulin-like growth factor-I in spinal cord of rats following unilateral sciatic nerve transection. [abstract no. OR-24] In: 10th International Congress of Endocrinology: San Francisco, CA, USA, 1996: 459

  87. Reynolds R, Wong V, et al. Brain-derived neurotrophic factor and eurotrophin −4/5 stimulate proliferation and c-Fos expression in cultured ligodendroglial progenitors: synergism with insulin-like growth factor-I 1997. In press

  88. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4: 883–94

    PubMed  CAS  Google Scholar 

  89. Galatzer A, Aran O, Nagelberg N, et al. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laro Z, Parks JS, editors. Lessons from Laron Syndrome (LS) 1966-1992. Pediatr Adolesc Endocrinol,Basel-New York: Karger, 1993: 53–60

    Google Scholar 

  90. Woods KA, Fraser NC, Postel-Vinay MC, et al. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996; 81: 1686–90

    Article  PubMed  CAS  Google Scholar 

  91. Laron Z, Lazar L, Galatzer A, et al. Growth hormone treatment accelerates head circumference growth in isolated GH deficiency. In: Hauspie R, Lindgren G, Falkner F, editors. Essays on Auxology. Hertfordshire, UK: Castlemead Publications, 1995: 489–95

    Google Scholar 

  92. Kranzler JH, Rosenbloom AL, Martinez V, et al. Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency. A controlled study in a genetically homogenous population. J Clin Endocrinol Metab 1998; 83: 1953–8

    Article  PubMed  CAS  Google Scholar 

  93. Laron Z, Galatzer A. A comment on normal intelligence in growth hormone receptor deficiency. (Letter). J Clin Endocrinol Metab 1998; 83: December (In Press)

  94. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology 1997; 49: 1621–30

    Article  PubMed  CAS  Google Scholar 

  95. Reid IR, Gluckman PD, Ibbertson HK. Insulin-like growth factor I and bone turnover in glucocortoid-treated and control subjects. Clin Endocrinol 1989; 30: 347–53

    Article  CAS  Google Scholar 

  96. Rubin CD, Reed B, Sakhaee K, et al. Treating a patient with Werner syndrome and osteoporosis using recombinant human insulin-like growth factor. Ann Int Med 1994; 121: 665–8

    PubMed  CAS  Google Scholar 

  97. Johansson AG, Lindh E, Blum WF, et al. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996; 81: 44–8

    Article  PubMed  CAS  Google Scholar 

  98. Jenkins RC, Ross RJM. The use of growth hormone and insulin-like growth factor-I in catabolic states. J Pediatr Endocrinol Metab 1997; 10: 131–6

    Article  Google Scholar 

  99. Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor site healing in severely burned children. Ann Surg 1990; 212: 424–31

    Article  PubMed  CAS  Google Scholar 

  100. Gore DC, Honeycutt D, Jahoor F, et al. Effect of exogenous growth hormone on whole body and isolated limb protein kinetics in burned patients. Arch Surg 1991; 126: 38–43

    Article  PubMed  CAS  Google Scholar 

  101. Krentz AT, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6: 245–51

    PubMed  CAS  Google Scholar 

  102. Lieberman SA, Butterfield GE, Harrison D, et al. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994; 78: 404–10

    Article  PubMed  CAS  Google Scholar 

  103. Cioffi WG, Gore DC, Rue LC, et al. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg 1994; 220: 310–9

    Article  PubMed  CAS  Google Scholar 

  104. Huang KF, Chung DH, Herndon DN. Insulin like growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg 1993; 128: 47–54

    Article  PubMed  CAS  Google Scholar 

  105. Tashiro T, Yamamori H, Takagi K, et al. Effects of growth hormone and insulin-like growth factor I on protein metabolism after experimental burn injury. Endocrinol Metab 1996; 3(Suppl A): 75

    Google Scholar 

  106. Shimoda N, Tashiro T, Yamamori H, et al. Effects of growth hormone and insulin-like growth factor-I on protein metabolism, gut morphology, and cell-mediated immunity in burned rats. Nutrition 1997; 13: 540–6

    Article  PubMed  CAS  Google Scholar 

  107. Goeters C, Mertes N, Tacke J, et al. Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Ann Surg 1995; 222: 646–53

    Article  PubMed  CAS  Google Scholar 

  108. Miell JP, Taylor AM, Jones J, et al. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol 1992; 37: 542–51

    Article  CAS  Google Scholar 

  109. Muta K, Krantz S, Bondourant MC, et al. Distinct roles of erythropoietin, insulin-like growth factor I and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1992; 94: 34–43

    Article  Google Scholar 

  110. Merchav S, Silvian-Drachsler I, Tatarsky I, et al. Comparative studies of the erythroid-potentiating effects of biosynthetic human insulin-like growth factors I and II. J Clin Endocrinol Metab 1992; 74: 447–52

    Article  PubMed  CAS  Google Scholar 

  111. Zegers BJM, Merchav S. Growth hormone and insulin-like growth factors in haemopoiesis, lymphopoiesis and immune function. Endocrinol Metab 1996; 3(Suppl. A): 105–9

    Google Scholar 

  112. Merchav S, Tatarksy I, Hochberg Z. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 1988; 81: 791–7

    Article  PubMed  CAS  Google Scholar 

  113. Merchav S, Lake M, Skottner A. Comparative studies of the granulopoietic enhancing effects of biosynthetic human insulin-like growth factors I and II. J Cell Physiol 1993; 157: 178–83

    Article  PubMed  CAS  Google Scholar 

  114. Clark R, Strasser J, McCabe S, et al. Insulin-like growth factor-I stimulation of lymphoporesis. J Clin Invest 1993; 92: 540–8

    Article  PubMed  CAS  Google Scholar 

  115. Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-I regulates pro-B cell differentiation. Blood 1992; 80: 1207–12

    PubMed  CAS  Google Scholar 

  116. Steeb CB, Shoubridge CA, Tivey DR et al. Systemic infusion of IGF-I or LR3 IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. Am J Physiol 1997; 272 (Gastointest Liver Physiol 35): G522–33

    PubMed  CAS  Google Scholar 

  117. Fholenhag K, Arrhenius-Nyberg V, Sjogren I, et al. Effects of insulin-like growth factor I (IGF-I) on the small intestine: a comparison between oral and subcutaneous administration in the weaned rat. Growth Factors 1997; 14: 81–8

    Article  PubMed  CAS  Google Scholar 

  118. Wolf E, Jehle PM, Weber MM, et al. Human insulin-like growth factor I (IGF-I) produced in the mammary glands of transgenic rabbits: yield, receptor binding, mitogenic activity, and effects on IGF-I binding proteins. Endocrinology 1997; 138: 307–13

    Article  PubMed  CAS  Google Scholar 

  119. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998; 35: 165–77

    Article  PubMed  CAS  Google Scholar 

  120. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6

    Article  PubMed  CAS  Google Scholar 

  121. Fleming RYD, Rutan RL, Jahoor F, et al. Effect of recombinant human growth hormone on catabolic hormones and free fatty acids following thermal injury. J Trauma 1992; 32: 698–703

    Article  PubMed  CAS  Google Scholar 

  122. Kupfer SR, Underwood LE, Baxter RC, et al. Enhancement of the anabolic effect of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91: 391–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laron, Z. Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1). BioDrugs 11, 55–70 (1999). https://doi.org/10.2165/00063030-199911010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911010-00006

Keywords

Navigation